ALK and neoplasm: For patients with EGFR mutation-positive, ALK rearrangement-positive or ROS1 rearrangement positive tumours first-line molecular targeted tyrosine kinase inhibitors are recommended, while patients with high PD-L1 expression in the tumour are suitable for pembrolizumab first-line treatment [6].